Modeling heart failure in animal models for novel drug discovery and development

被引:10
|
作者
Janssen, Paul M. L. [1 ,2 ,3 ]
Elnakish, Mohammad T. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Animal model; human heart failure; ischemia; hypertension; contraction; LEFT-VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION MODEL; CONTRACTILE DYSFUNCTION; ANGIOTENSIN-II; CARDIAC-FUNCTION; CANINE MODEL; IN-VIVO; FORCE; MOUSE; RAT;
D O I
10.1080/17460441.2019.1582636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: When investigating drugs that treat heart diseases, it is critical when choosing an animal model for the said model to produce data that is translatable to the human patient population, while keeping in mind the principles of reduction, refinement, and replacement of the animal model in the research. Areas covered: In this review, the authors focus on mammalian models developed to study the impact of drug treatments on human heart failure. Furthermore, the authors address human patient variability and animal model invariability as well as the considerations that need to be made regarding choice of species. Finally, the authors discuss some of the most common models for the two most prominent human heart failure etiologies; increased load on the heart and myocardial ischemia. Expert opinion: In the authors' opinion, the data generated by drug studies is often heavily impacted by the choice of species and the physiologically relevant conditions under which the data are collected. Approaches that use multiple models and are not restricted to small rodents but involve some verification on larger mammals or on human myocardium, are needed to advance drug discovery for the very large patient population that suffers from heart failure.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [31] Animal models of pain migraine in drug discovery
    Munro, Gordon
    Jansen-Olesen, Inger
    Olesen, Jes
    DRUG DISCOVERY TODAY, 2017, 22 (07) : 1103 - 1111
  • [32] Animal models of skin disease for drug discovery
    Avci, Pinar
    Sadasivam, Magesh
    Gupta, Asheesh
    De Melo, Wanessa C. M. A.
    Huang, Ying-Ying
    Yin, Rui
    Chandran, Rakkiyappan
    Kumar, Raj
    Otufowora, Ayodeji
    Nyame, Theodore
    Hamblin, Michael R.
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (03) : 331 - 355
  • [33] Animal models of invasive aspergillosis for drug discovery
    Paulussen, Caroline
    Boulet, Gaelle A. V.
    Cos, Paul
    Delputte, Peter
    Maes, Louis J. R. M.
    DRUG DISCOVERY TODAY, 2014, 19 (09) : 1380 - 1386
  • [34] Animal models of chronic heart failure
    Muders, F
    Elsner, D
    PHARMACOLOGICAL RESEARCH, 2000, 41 (06) : 605 - 612
  • [35] Animal models of depression: Relevance to drug discovery
    Norman, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 40 - 40
  • [36] Small animal models of heart failure
    Riehle, Christian
    Bauersachs, Johann
    CARDIOVASCULAR RESEARCH, 2019, 115 (13) : 1838 - 1849
  • [37] Animal models of right heart failure
    Andersen, Asger
    van der Feen, Diederik E.
    Andersen, Stine
    Schultz, Jacob Gammelgaard
    Hansmann, Georg
    Bogaard, Harm Jan
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (05) : 1561 - 1579
  • [38] Large animal models of heart failure
    Power, JM
    Tonkin, AM
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (03): : 395 - 402
  • [39] Animal Models of Heart Failure: the Forgotten Animal Model
    Chandrasekera, Charukeshi
    FASEB JOURNAL, 2016, 30
  • [40] Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches
    Rasooly, Danielle
    Pereira, Alexandre C.
    Joseph, Jacob
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)